Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 8 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

25%

2 trials in Phase 3/4

Results Transparency

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A

4(57.1%)

Phase 4

1(14.3%)

Phase 3

1(14.3%)

Phase 2

1(14.3%)

7Total

N/A(4)

Phase 4(1)

Phase 3(1)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT06219291Unknown

Preventing the Progression of Multiple Sclerosis: Early Rehabilitative Treatment and Multimodal Assessment - Part A

Role: collaborator

NCT06056960Not ApplicableUnknown

Preventing the Progression of Multiple Sclerosis: Early Rehabilitative Treatment and Multimodal Assessment - Part B

Role: collaborator

NCT04032431Not ApplicableUnknown

Upper Limb Telerehabilitation With Virtual Reality in Multiple Sclerosis

Role: collaborator

NCT04027491Not ApplicableUnknown

Virtual Reality for Upper Limb Rehabilitation in Multiple Sclerosis

Role: collaborator

NCT01492491Phase 3Completed

Collaborative Research on HFR High Flux

Role: lead

NCT02404454Not ApplicableUnknown

Prevention of Intrauterine Adhesions After Hysteroscopic Metroplasty With Autocross-linked Hyaluronic Acid Gel

Role: collaborator

NCT01784549Phase 2Unknown

Customized Neoadjuvant Versus Standard Chemotherapy in NSCL Patients With Resectable Stage IIIA (N2)Disease

Role: collaborator

NCT00800761Phase 4Completed

Intensive Combined Chelation Therapy for Iron-Induced Cardiac Disease in Patients With Thalassemia Major

Role: collaborator

All 8 trials loaded